• Sobi reported its Phase 3 REDUCE-2 trial met its primary goal, with pozdeutinurad lowering serum urate in patients with uncontrolled gout.
• Reductions persisted for 12 months; more treated patients reached target levels than with placebo.
• Safety was generally comparable to placebo, supporting the once-daily oral treatment’s development.
• Detailed results will be presented at ACR Convergence on November 11, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.